The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-24 and is reviewed periodically as new material appears.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
spindle apparatus The cytoskeletal structure that forms during cell division in eukaryotic cells, consisting of a network of long, flexible microtubules extending from each pole of the parent cell and attaching to kinetochores at the centromeres of homologous chromosomes or sister chromatids near the cell equator. As the microtubules shorten, they pull the chromosomes apart, separating them into different daughter cells. Proper formation of this apparatus is critical in both mitosis and meiosis, where it is respectively referred to as the mitotic spindle and meiotic spindle.
== Aftermath == In 1976, McTavish married, becoming Jessie Gordon. In 1984, she was restored to the professional register for nursing, midwifery and health visiting. She continued her career in nursing.
After the Polish–Russian Treaty of Andrusovo split Ukraine along the Dnieper River in 1667, Ukrainian Cossacks were known as Left-bank and Right-bank Cossacks. The ataman had executive powers, and in wartime was the supreme commander in the field. Legislative power was given to the Band Assembly (Rada). The senior officers were called starshyna. In the absence of written laws, the Cossacks were governed by the "Cossack Traditions" – the common, unwritten law. Cossack society and government were heavily militarized. The nation was called a host (vois'ko, or viys'ko, translated as "army"). The people and territories were subdivided into regimental and company districts, and village posts (polky, sotni, and stanytsi). A unit of a Cossack troop could be called a Kurin. Each Cossack settlement, alone or in conjunction with neighboring settlements, formed military units and regiments of light cavalry or, in the case of Siberian Cossacks, mounted infantry. They could respond to a threat on very short notice. A high regard for education was a tradition among the Cossacks of Ukraine. In 1654, when Macarius III Ibn al-Za'im, the Patriarch of Antioch, traveled to Moscow through Ukraine, his son, Deacon Paul Allepscius, wrote the following report:
=== Peroxide stress response === In response to an increased flux of hydrogen peroxide and other organic peroxides such as tert-butyl hydroperoxide and cumene hydroperoxide, peroxide stimulon gets activated. Studies of E. coli response to H2O2 have shown that exposure to H2O2 elevated mRNA levels of 140 genes, of which 30 genes are members of the OxyR regulon. The genes include many genes coding for metabolic enzymes and antioxidant enzymes demonstrating the role of these enzymes in reorganization of metabolism under stress conditions.
== Sites in the body == Quantitatively, the smooth endoplasmic reticulum of the liver cell is the principal organ of drug metabolism, although every biological tissue has some ability to metabolize drugs. Factors responsible for the liver's contribution to drug metabolism include that it is a large organ, that it is the first organ perfused by chemicals absorbed in the gut, and that there are very high concentrations of most drug-metabolizing enzyme systems relative to other organs. If a drug is taken into the gastrointestinal tract (GI tract), where it enters the hepatic portal system through the portal vein, it becomes well-metabolized and is said to show the first pass effect. Other sites of extrahepatic drug metabolism include epithelial cells of the GI tract, lungs, kidneys, and skin. These sites are usually responsible for localized toxicity reactions.
Sources: en.wikipedia.org
== Further reading == "Clean Water Act Analytical Methods". EPA. 2022-07-27. "Hazardous Waste Test Methods / SW-846". EPA. 2022-06-15. Eaton, Andrew D.; Greenberg, Arnold E.; Rice, Eugene W.; Clesceri, Lenore S.; Franson, Mary Ann H., eds. (2005). Standard Methods For the Examination of Water and Wastewater (21 ed.). American Public Health Association. ISBN 978-0-87553-047-5. Also available on CD-ROM and online by subscription.
== History == The first successful mechanically refrigerated trucks were made for the ice cream industry in 1925. American inventor Frederick McKinley Jones is known to be the first person to invent a refrigerated truck. There were around 4 million refrigerated road vehicles in use in 2010 worldwide.
Either directly or indirectly, wine yeast can be a culprit behind a wide variety of wine faults. These can include the presence of "off flavors" and aromas that can be the by-product of some "wild yeast" fermentation such as those by species within the genera of Kloeckera and Candida. Even the common wine yeast Saccharomyces cerevisiae can be behind some wine faults with some strains of the yeast known to produce higher than ideal levels of acetic acid, acetaldehyde and volatile sulfur compounds such as thiols. Also any yeast can have a low tolerance to nutritional deficiencies, temperature fluctuation or extremes and excessive or low sugar levels that may lead to a stuck fermentation. In the presence of oxygen several species of Candida and Pichia can create a film surface on top of the wine in the tank of barrel. Allowed to go unchecked, these yeasts can rapidly deplete the available free sulfur compounds that keeps a wine protected from oxidation and other microbial attack. The presence of these yeasts is often identified by elevated levels of volatile acidity, particularly acetic acid. Some strains of Pichia will metabolize acetic acid (as well as ethyl acetate and isoamyl acetate that may also be produced) with the side-effect of substantially decreasing the titratable acidity and shifting the pH of wine upwards to levels that make the wine prone to attack by other spoilage microbes. Commonly called "film yeast", these yeasts are distinguished from the flor sherry yeast that are usually welcomed by winemakers in producing the delicate fino-style wines.
=== Cancer === A meta-analysis concluded that supplementation with β-carotene does not appear to decrease the risk of cancer overall, nor specific cancers including: pancreatic, colorectal, prostate, breast, melanoma, or skin cancer generally. High levels of β-carotene may increase the risk of lung cancer in current and former smokers. Results are not clear for thyroid cancer.
Diabetes – general term referring to all states characterized by hyperglycemia. It can be of the following types: Type 1 diabetes – autoimmune-mediated destruction of insulin-producing β-cells in the pancreas, resulting in absolute insulin deficiency Type 2 diabetes – either inadequate insulin production by the β-cells or insulin resistance or both because of reasons not completely understood. there is correlation with diet, with sedentary lifestyle, with obesity, with age and with metabolic syndrome. Causality has been demonstrated in multiple model organisms including mice and monkeys; importantly, non-obese people do get Type 2 diabetes due to diet, sedentary lifestyle and unknown risk factors, though this may not be a causal relationship. it is likely that there is genetic susceptibility to develop Type 2 diabetes under certain environmental conditions Other types of impaired glucose tolerance (see Diabetes) Insulinoma – a tumor of beta cells producing excess insulin or reactive hypoglycemia. Metabolic syndrome – a poorly understood condition first called syndrome X by Gerald Reaven. It is not clear whether the syndrome has a single, treatable cause, or is the result of body changes leading to type 2 diabetes. It is characterized by elevated blood pressure, dyslipidemia (disturbances in blood cholesterol forms and other blood lipids), and increased waist circumference (at least in populations in much of the developed world).
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.